AUXL
Auxilium Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Nov. 19, 2014, 11:55 AM
    • The U.S. Federal Trade Commission terminates the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for Endo International's (ENDP -0.8%) intended acquisition of Auxilium Pharmaceuticals (AUXL +0.6%).
    • As previously announced, Endo will acquire all of the outstanding shares of Auxilium for $33.25 in a cash-and-stock deal valued at $2.6B. The transaction should close in Q1 2015.
    • Previously: Auxilium agrees to sale to Endo for $2.6B
    | Nov. 19, 2014, 11:55 AM
  • Oct. 9, 2014, 6:48 AM
    • The stock and cash deal works out to a price of $33.25 for each share of Auxilium (NASDAQ:AUXL) vs. last night's close of $29.76, and represents a 55% premium to AUXL's closing price on Sept. 16, the day Endo International (NASDAQ:ENDP) made public its purchase proposal.
    • Endo's earlier rejected bid had been for $2.2B.
    • Auxilium owners may elect to receive consideration of all stock (0.488 ENDP shares for each share of AUXL), or all cash, or an equal mix of stock and cash.
    • Previously: Auxilium says Endo offer a bit light but is willing to talk
    | Oct. 9, 2014, 6:48 AM | 1 Comment
  • Sep. 22, 2014, 12:18 PM
    • Auxilium Pharmaceuticals' (AUXL -0.3%) BOD says that Endo International's (ENDP -1.7%$2.2B bid "significantly undervalues" the company. Despite implementing a poison pill takeover defense, it says that it maintains the right to engage in discussions with Endo. ENDP says that it is willing to work with AUXL on a deal.
    • A marriage with Endo would probably scupper Auxilium's agreement to merge with Canadian eye drug manufacturer QLT, Inc.
    | Sep. 22, 2014, 12:18 PM
  • Sep. 17, 2014, 8:29 AM
    • Auxilium Pharmaceuticals (NASDAQ:AUXL) is up 45% premarket on robust volume in response to Endo's bid.
    | Sep. 17, 2014, 8:29 AM
  • Sep. 16, 2014, 5:32 PM
    • Endo International (ENDP +0.9%) submits a proposal to Auxilium Pharmaceuticals (AUXL -1.6%) to acquire it for $28.10 per share in cash. The total value of the transaction would be $2.2B or a 31% premium to today's closing price.
    • AUXL is up 42% AH on robust volume. ENDP is up 5% AH on heavy volume.
    | Sep. 16, 2014, 5:32 PM | 2 Comments
  • Jun. 26, 2014, 8:22 AM
    • Auxilium Pharmaceuticals (AUXL) and Canadian biotech QLT Inc. enter into a definitive agreement to merge. Under the terms of the agreement, QLT will remain incorporated in British Columbia and will be renamed "New Auxilium." Current AUXL shareholders will be receive 3.1359 QLT shares for each AUXL share. AUXL shareholders will own ~76% of the combined entity and QLT shareholders will own ~24%.
    • Auxilium's current management team will lead the new company. Shares will trade on NASDAQ under "AUXL" and QLT will be delisted from the Toronto Stock Exchange.
    • AUXL shares are up 17% premarket on robust volume.
    | Jun. 26, 2014, 8:22 AM